Skip to main content

Valirx Amends License for VAL201 with Cancer Research Technology

20 Dec 2021

Videos and audiocasts

Dr Suzy Dilly, CEO of Valirx, discusses the amendment of the VAL201 license which will allow ValiRx and TheoremRx Inc. to proceed to full license without further CRT involvement.

Click here for the full BRR Media Video Update.